List view / Grid view
30 November 2011 | By Teva
A portion of the profits from Ranbaxy’s sales of Atorvastatin Calcium Tablets during Ranbaxy’s 180-day first-to-file exclusivity period, will be paid to Teva...
30 November 2011 | By Roche
Results from studies to be presented at SABCS...
29 November 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. FDA has accepted for review a NDA for ELIQUIS® (apixaban)...
29 November 2011 | By Sanofi
Sanofi organizes the 10th Edition of the Pan-African Conference against Malaria with representatives of 34 African Countries...
29 November 2011 | By AstraZeneca
The European Commission has granted marketing authorisation for KOMBOGLYZE™...
28 November 2011 | By Bristol-Myers Squibb Company
The European Commission has approved ONGLYZA® (saxagliptin)...
28 November 2011 | By AstraZeneca
MedImmune Ventures closes investment in Australian company, NeuProtect Pty Ltd...
28 November 2011 | By Daniel J Edelman Ltd
The European Commission has granted marketing authorisation for EDURANT® (rilpivirine)...
28 November 2011 | By F T I Consulting
World’s leading researchers work together on therapeutic advances in neuroscience...
28 November 2011 | By Novartis
Rasitrio®, the first triple combination of aliskiren, amlodipine and hydrochlorothiazide in a single pill has received approval...
28 November 2011 | By Abbott
Abbott announced that it will expand its existing agreement with GSK...
28 November 2011 | By Gilead Sciences Inc
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Eviplera®...
23 November 2011 | By kdm communications limited
Syrris is pleased to announce the release of its new Asia flow chemistry reactors catalogue...
23 November 2011 | By Weizmann UK
The clinical trial was random, regulated, double-blinded and broad-based...
22 November 2011 | By Pfizer
Lead program includes novel investigational compound for prevention/treatment of skin scarring...
